JP2023508327A5 - - Google Patents
Info
- Publication number
- JP2023508327A5 JP2023508327A5 JP2022538216A JP2022538216A JP2023508327A5 JP 2023508327 A5 JP2023508327 A5 JP 2023508327A5 JP 2022538216 A JP2022538216 A JP 2022538216A JP 2022538216 A JP2022538216 A JP 2022538216A JP 2023508327 A5 JP2023508327 A5 JP 2023508327A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- unsubstituted
- substituted
- product according
- pharmaceutical product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962951991P | 2019-12-20 | 2019-12-20 | |
| US62/951,991 | 2019-12-20 | ||
| PCT/US2020/065401 WO2021127039A1 (en) | 2019-12-20 | 2020-12-16 | Combinations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023508327A JP2023508327A (ja) | 2023-03-02 |
| JP2023508327A5 true JP2023508327A5 (enExample) | 2023-12-25 |
| JP7794448B2 JP7794448B2 (ja) | 2026-01-06 |
Family
ID=76478158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022538216A Active JP7794448B2 (ja) | 2019-12-20 | 2020-12-16 | 組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230068370A1 (enExample) |
| EP (1) | EP4069241A4 (enExample) |
| JP (1) | JP7794448B2 (enExample) |
| KR (1) | KR20220119658A (enExample) |
| CN (1) | CN115087447A (enExample) |
| AU (1) | AU2020407514A1 (enExample) |
| BR (1) | BR112022012278A2 (enExample) |
| CA (1) | CA3165350A1 (enExample) |
| IL (1) | IL294074A (enExample) |
| MX (1) | MX2022007629A (enExample) |
| TW (1) | TWI895318B (enExample) |
| WO (1) | WO2021127039A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020384291A1 (en) | 2019-11-15 | 2022-05-26 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| WO2022011391A1 (en) | 2020-07-09 | 2022-01-13 | Recurium Ip Holdings, Llc | Salts and forms of a wee1 inhibitor |
| CN116462687B (zh) * | 2022-01-18 | 2025-01-07 | 江苏天士力帝益药业有限公司 | Wee1抑制剂及其制备和用途 |
| WO2023147297A2 (en) * | 2022-01-25 | 2023-08-03 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
| TW202543650A (zh) | 2024-03-08 | 2025-11-16 | 美商海爾達醫療運營公司 | 異雙官能化合物及其在治療疾病中之用途 |
| WO2025193930A1 (en) * | 2024-03-14 | 2025-09-18 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015095250A1 (en) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Combination cancer therapy of wee1 and mtor inhibitors |
| TWI874834B (zh) | 2014-12-18 | 2025-03-01 | 瑞士商赫孚孟拉羅股份公司 | 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途 |
| CN109843882A (zh) * | 2016-06-16 | 2019-06-04 | 豪夫迈·罗氏有限公司 | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 |
| EP3640251B1 (en) * | 2016-10-24 | 2021-12-08 | Astrazeneca AB | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
| CN109422754A (zh) * | 2017-08-24 | 2019-03-05 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
| WO2019165204A1 (en) * | 2018-02-23 | 2019-08-29 | Newave Pharmaceutical Inc. | 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidine-3-one compounds as inhibitors of wee-1 kinase |
| EP4566612A3 (en) * | 2018-03-09 | 2025-08-20 | Recurium IP Holdings, LLC | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
-
2020
- 2020-12-16 KR KR1020227024837A patent/KR20220119658A/ko active Pending
- 2020-12-16 US US17/757,483 patent/US20230068370A1/en active Pending
- 2020-12-16 JP JP2022538216A patent/JP7794448B2/ja active Active
- 2020-12-16 BR BR112022012278A patent/BR112022012278A2/pt unknown
- 2020-12-16 CN CN202080095164.0A patent/CN115087447A/zh active Pending
- 2020-12-16 IL IL294074A patent/IL294074A/en unknown
- 2020-12-16 EP EP20903410.7A patent/EP4069241A4/en active Pending
- 2020-12-16 WO PCT/US2020/065401 patent/WO2021127039A1/en not_active Ceased
- 2020-12-16 AU AU2020407514A patent/AU2020407514A1/en active Pending
- 2020-12-16 CA CA3165350A patent/CA3165350A1/en active Pending
- 2020-12-16 MX MX2022007629A patent/MX2022007629A/es unknown
- 2020-12-18 TW TW109145123A patent/TWI895318B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023508327A5 (enExample) | ||
| JP2023507797A5 (enExample) | ||
| JP7348906B2 (ja) | フェロトーシス誘導活性を有する化合物およびそれらの使用方法 | |
| TWI874834B (zh) | 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途 | |
| JP2023512113A5 (enExample) | ||
| CN114599361A (zh) | Prmt5抑制剂的药物组合物 | |
| JP2019510832A5 (enExample) | ||
| JP2023508325A5 (enExample) | ||
| AU2022376939A1 (en) | Combination therapy for treating abnormal cell growth | |
| TWI755788B (zh) | 類鐸受體促效劑 | |
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2023508328A5 (enExample) | ||
| WO2022170060A1 (en) | Combination therapy for treating abnormal cell growth | |
| RU2007134396A (ru) | Химические соединения | |
| WO2017216279A1 (en) | Heteroaryl estrogen receptor modulators and uses thereof | |
| US10654867B2 (en) | Heteroaryl estrogen receptor modulators and uses thereof | |
| JP2015166354A (ja) | 増殖性疾患治療用非対称ピロロベンゾジアゼピン−二量体 | |
| JP2006519862A5 (enExample) | ||
| JP2023508332A5 (enExample) | ||
| EP3749654B1 (en) | Substituted benzothiophene analogs as selective estrogen receptor degraders | |
| ES2987356T3 (es) | Compuestos antiproliferación y usos de los mismos | |
| JPWO2020032105A5 (enExample) | ||
| KR20080033501A (ko) | 증식성 질환 또는 염증의 치료를 위한3,11ｂ-시스-디히드로테트라베나진 | |
| US20190117663A1 (en) | Compositions and methods for treating cancer | |
| RU2024112238A (ru) | Применение комбинированной терапии для лечения рака |